Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
The primary objective of the open-label, dose-escalation study is to investigate the safety of single-dose monotherapy and repeated-dose of KHK2375 combined with exemestane in female subjects with advanced or recurrent breast cancer. The secondary objective is to investigate the pharmacokinetics and efficacy.
Breast Cancer
DRUG: KHK2375|DRUG: Exemestane
Number and percentage of subjects with treatment-emergent adverse events including dose-limiting toxicities and serious adverse events, Assessed up to 28 days after study discontinuation
Pharmacokinetics of KHK2375 [maximum concentration (Cmax)], Pre-dose, Cycle 0 Days 1, 2, 4, 6, Cycle 1 Days 1, 2, 4, 6, 8, 15, 22 and Cycle 2 Day 1|Pharmacokinetics of KHK2375 [Area under the curve (AUC)], Pre-dose, Cycle 0 Days 1, 2, 4, 6, Cycle 1 Days 1, 2, 4, 6, 8, 15, 22 and Cycle 2 Day 1|Pharmacokinetics of KHK2375 [Half-life (t1/2)], Pre-dose, Cycle 0 Days 1, 2, 4, 6, Cycle 1 Days 1, 2, 4, 6, 8, 15, 22 and Cycle 2 Day 1
The primary objective of the open-label, dose-escalation study is to investigate the safety of single-dose monotherapy and repeated-dose of KHK2375 combined with exemestane in female subjects with advanced or recurrent breast cancer. The secondary objective is to investigate the pharmacokinetics and efficacy.